1. Home
  2. UPWK vs AVLN Comparison

UPWK vs AVLN Comparison

Compare UPWK & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Upwork Inc.

UPWK

Upwork Inc.

SELL

Current Price

$10.34

Market Cap

1.1B

Sector

Technology

ML Signal

SELL

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

SELL

Current Price

$26.91

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
UPWK
AVLN
Founded
1998
2011
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2018
2026

Fundamental Metrics

Financial Performance
Metric
UPWK
AVLN
Price
$10.34
$26.91
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$10.64
★ $61.80
AVG Volume (30 Days)
★ 3.1M
392.4K
Earning Date
11-02-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.69
N/A
Revenue
★ $787,784,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.91
★ N/A
Revenue Growth
★ 2.40
N/A
52 Week Low
$7.44
$22.24
52 Week High
$22.84
$40.17

Technical Indicators

Market Signals
Indicator
UPWK
AVLN
Relative Strength Index (RSI) 69.95 50.30
Support Level $7.81 $24.90
Resistance Level $11.79 $28.52
Average True Range (ATR) 0.42 1.81
MACD 0.09 0.43
Stochastic Oscillator 76.11 72.83

Price Performance

Historical Comparison
UPWK
AVLN

About UPWK Upwork Inc.

Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes and connects businesses with AI-enabled talent across every on-demand work type, including freelance, agency, fractional, and payrolled. The business generates revenue from Talent and Clients across the USA, India, Pakistan, the Philippines and the rest of the world. Maximum revenue of the company is derived from Talent segment.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: